Truist Financial reiterated their buy rating on shares of Adicet Bio (NASDAQ:ACET – Free Report) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $27.00 price objective on the stock. Several other research firms have also weighed in on ACET. StockNews.com started coverage on shares of Adicet Bio in a […]

Related Keywords

Carll Gordon , Adicet Bio , Carlyle Group Inc , Securities Exchange Commission , Blackrock Inc , Adicet Bio Inc , Jpmorgan Chase Co , Adicet Bio Company Profile , Truist Financial , Free Report , Bio Trading Down , Get Free Report , Director Carl , Exchange Commission , State Street Corp , Street Corp , Adicet Bio Daily , Nasdaq Acet , Facet , Medical , 00444610 , Reiterated Rating , Truist Financial Co ,